Clinical trials: Pancreatic Fibrosis
Cystic Fibrosis-related Diabetes, Cystic Fibrosis
Continuous Glucose Monitoring and OGTT Screen for Cystic Fibrosis Related Diabetes in Cystic Fibrosis
Cystic Fibrosis (CF) related diabetes (CFRD) is a unique form of diabetes mellitus, different from type 1 diabetes and type 2 diabetes.
- Trial name
- NCT06560463
- Testing
- Access to Dexcom G7 CGM Data
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Medical College of Wisconsin
Exocrine Pancreatic Insufficiency, Cystic Fibrosis
Control of Steatorrhea in Participants With Cystic Fibrosis and Exocrine Pancreatic Insufficiency
This study by Aptalis (formerly Axcan) assesses the efficacy and safety of Panzytrat® 25,000 compared to Kreon® 25,000 in the control of steatorrhea in participants with cystic fibrosis (CF) and exocrine pancreatic insufficiency…
- Trial name
- NCT01327703
- Testing
- Panzytrat® 25,000, Kreon® 25,000
- Where
- 13 sites in Germany, Poland
- Volunteers
- 87 people
- Sponsor
- Forest Laboratories
Cystic Fibrosis
A Study Evaluating the Long-Term Safety of Elexacaftor Combination Therapy
This study evaluate the long-term safety and tolerability of elexacaftor (ELX)/tezacaftor (TEZ)/ ivacaftor (IVA) triple combination (TC) in participants with cystic fibrosis (CF) who are homozygous for F508del.
- Trial name
- NCT04362761
- Testing
- ELX/TEZ/IVA, IVA
- Where
- 29 sites in Australia, Belgium and 2 more
- Volunteers
- 172 people
- Sponsor
- Vertex Pharmaceuticals Incorporated
Cystic Fibrosis
Efficacy and Safety of 28 or 56 Day Treatment for Pseudomonas Aeruginosa in Children With Cystic Fibrosis
This study assessed time to recurrence of infection with Pseudomonas aeruginosa following treatment of the initial infection with tobramycin nebuliser solution.
- Trial name
- ELITE (NCT00391976)
- Testing
- Tobramycin solution for inhalation 300 mg
- Volunteers
- 123 people
- Sponsor
- Novartis
Cystic Fibrosis
Assessment of Cognitive Function and Exercise Capacity in Cystic Fibrosis
No studies in the literature have investigated the simultaneous effects of cognitive function, exercise capacity and arterial stiffness in adult patients with CF.
- Trial name
- NCT06175182
- Where
- Turkey (Türkiye)
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Hacettepe University
Cystic Fibrosis, CFTR Gene Mutation
Validation of Therapeutic Efficacy Targeting the Splicing Variants in Cystic Fibrosis and CFTR Pathologies
Cystic Fibrosis, an inherited autosomal recessive disease, arises from mutations in the CFTR gene. For intronic mutations affecting splicing events, oligonucleotides therapy has the potential to restore the production of the full…
- Trial name
- ONB-CFTR (NCT05100823)
- Testing
- Nasal cells sampling, Rectal biopsy sampling
- Where
- France
- Volunteers
- 16 people
- Sponsor
- University Hospital, Montpellier
Cystic Fibrosis
Study of GLPG1837 in Subjects With Cystic Fibrosis (G551D Mutation)
32 cystic fibrosis patients with the G551D mutation will be treated for 4 weeks, consisting of three consecutive treatment periods: two 1-week periods followed by one 2-week period, evaluating one dose of GLPG1837 each.
- Trial name
- SAPHIRA1 (NCT02707562)
- Testing
- GLPG1837 dose 1, GLPG1837 dose 2, GLPG1837 dose 3
- Where
- 16 sites in Australia, Czechia and 3 more
- Volunteers
- 26 people
- Sponsor
- Lakefront Biotherapeutics NV
Cystic Fibrosis
Renal Failure Following Lung Transplantation in Cystic Fibrosis Patients
With this retrospective observational cohort study, we performed a longitudinal assessment of the renal function of the adult CF patients who underwent LUTX, aiming 1) to describe possible risk factors associated with…
- Trial name
- AKI_LUTX (NCT05001841)
- Testing
- Lung Transplantation
- Where
- Italy
- Volunteers
- 85 people
- Sponsor
- Policlinico Hospital
Cystic Fibrosis
Study of Uridine Triphosphate (UTP) as an Aerosol Spray for Cystic Fibrosis
OBJECTIVES: I. Determine the stability of uridine triphosphate (UTP) and examine the metabolism of exogenous nucleotides on airway epithelial surfaces in patients with cystic fibrosis. II.
- Trial name
- NCT00004705
- Testing
- amiloride, uridine
- Sponsor
- FDA Office of Orphan Products Development
Cystic Fibrosis
Psychological Study in Children With Mucoviscidosis
Cystic fibrosis is the most common serious genetic disease in Europe. It is a multi-disciplinary disease, causing multiple organ damage. It is a painful disease and a source of anxiety and depression.
- Trial name
- DoulAnxMuco (NCT05948488)
- Testing
- Questionnaires
- Where
- France
- Volunteers
- 160 people
- Sponsor
- University Hospital, Toulouse
Pancreatic Neoplasm, Magnetic Resonance Imaging
MRE for Diagnosis of Pancreatic Masses
Pancreatic ductal adenocarcinoma (PDAC) accounts for 85-95% of pancreatic cancer and is one of the deadliest tumors in the world, with a survival rate of less than 8%, and identifying key prognostic or predictive factors…
- Trial name
- MREDPCM (NCT06526442)
- Testing
- magnetic resonance imaging
- Where
- China
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Yu Shi
Cystic Fibrosis
Restarting Triple Therapy With Robust Monitoring for Adverse Events (RETRIAL)
RETRIAL is a multi-site observational study of people with Cystic Fibrosis (PWCF) ages 6 and up starting the new triple-therapy modulator (vanzacaftor/tezacaftor/deutivacaftor (VTD)), after having experienced neuropsychiatric…
- Trial name
- NCT06683092
- Testing
- RETRIAL-Mental Health, RETRIAL-Liver, RETRIAL-Neuro
- Where
- 18 sites in United States
- Volunteers
- 200 people
- Sponsor
- Boston Children's Hospital
Cystic Fibrosis (CF)
MRI Parameters as Biomarkers in Cystic Fibrosis (FEMPTO)
Cystic fibrosis (CF) is an inherited condition that affects several organs, including the gut. People with CF often experience uncomfortable digestive symptoms such as bloating, gas, abdominal pain, and constipation.
- Trial name
- FEMPTO (NCT07780344)
- Testing
- Linaclotide 290 micrograms
- Where
- United Kingdom
- Volunteers
- 12 people
- Sponsor
- University of Nottingham
Cystic Fibrosis
A Phase 1/2 Study of VX-522 in Participants With Cystic Fibrosis (CF)
The purpose of this study is to evaluate the safety, and tolerability and efficacy of VX-522 in participants 18 years of age and older with cystic fibrosis and a cystic fibrosis transmembrane conductance regulator (CFTR) genotype…
- Trial name
- NCT05668741
- Testing
- VX-522 mRNA therapy, IVA
- Where
- 26 sites in United States, Australia and 5 more
- Volunteers
- 26 people
- Sponsor
- Vertex Pharmaceuticals Incorporated
Cystic Fibrosis
Clinical Study to Investigate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of POL6014 in Patients With CF
"This is a randomised, double-blind, placebo-controlled multi-centre study to investigate safety and tolerability and to provide pharmacokinetic and pharmacodynamics information of orally inhaled multiple doses (80 mg, 160 mg or…
- Trial name
- NCT03748199
- Testing
- POL6014
- Where
- 4 sites in Germany
- Volunteers
- 32 people
- Sponsor
- Santhera Pharmaceuticals
Cystic Fibrosis, Exocrine Pancreatic Insufficiency
Study of Pancreatic Enzyme Product in Pediatric Participants With Cystic Fibrosis and Exocrine Pancreatic Insufficiency
This is an open-label study to evaluate the efficacy and safety of Aptalis' (formerly Eurand) pancreatic enzyme product (PEP) microtabs in pediatric participants under age 7 with cystic fibrosis (CF) and exocrine pancreatic…
- Trial name
- NCT00981214
- Testing
- EUR-1008 (APT-1008)
- Where
- 14 sites in United States
- Volunteers
- 19 people
- Sponsor
- Forest Laboratories
Cystic Fibrosis, Airway Clearance Impairment
IPV vs CPT for Airway Clearance During CF Exacerbation
Intrapulmonary Percussive Ventilation (IPV) will show greater improvements in Forced Expiatory Volume in 1 second (FEV1) shorter duration of stay, and greater time to next pulmonary exacerbation in pediatric Cystic Fibrosis…
- Trial name
- NCT03261219
- Testing
- Intrapulmonary Percussive ventilation, Chest Physiotherapy Vest (Incourage)
- Sponsor
- University of Florida
Cystic Fibrosis in Children
Effect of Antioxidant Docosahexaenoic Acid (DHA) in Cystic Fibrosis Patients
This study evaluates the effect of antioxidant docosahexaenoic acid (DHA) in patients with cystic fibrosis. Half of participants will receive DHA, while the other half will receive placebo.
- Trial name
- NCT04987567
- Testing
- ANTIOXIDANT DHA TRIGLYCERIDE (TRIDOCOSAHEXAENOINE-AOX®)
- Where
- Spain
- Volunteers
- 22 people
- Sponsor
- Corporacion Parc Tauli
Cystic Fibrosis
Effects of a Telerehabilitation Approach in Children With Cystic Fibrosis
Patients with cystic fibrosis aged 6-13 will be recruited and randomized into two groups: one will receive telerehabilitation sessions including postural, breathing and high-intensity interval training exercises and one will be…
- Trial name
- NCT04683809
- Testing
- Telerehabilitation
- Volunteers
- 30 people
- Sponsor
- Marmara University
Cystic Fibrosis
Comparing Chest Images From MRI to CT in Patients With Cystic Fibrosis (CF)
The purpose of this research is to learn more about the heart and blood vessels in the lungs of people with cystic fibrosis (CF).
- Trial name
- NCT01860872
- Where
- United States
- Volunteers
- 64 people
- Sponsor
- Children's Hospital Medical Center, Cincinnati
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.